Wieviel CT braucht die PET/CT?

Literatur
1 Antoch G, Freudenberg LS, Beyer T. et al. To Enhance or Not to Enhance? ¹⁸F-FDG and CT Contrast Agents in Dual-Modality ¹⁸FFDG PET/CT. J Nucl Med 2004; 45: 56S-65S.
2 Beyer T, Antoch G, Muller S. et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004; 45: 25S-35S.
3 Beyer T, Townsend DW, Brun T. et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-79.
4 Burgener FA, Hamlin DJ. Intravenous contrast enhancement in computed tomography of pelvic malignancies. rofo Fortschr Geb Röntgenstr Nuklearmed 1981; 134: 656-61.
5 Coppenrath E, Schmid C, Brandl R. et al. Spiral CT of the abdomen: weight-adjusted dose reduction. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2001; 173: 52-6.
6 Dean PB. Contrast media in body computed tomography: experimental and theoretical background, present limitations, and proposals for improved diagnostic efficacy. Invest Radiol 1980; 15: S164-9.
7 Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004; 45 (Suppl. 01) 66S-71S.
8 Gorges R, Antoch G, Brandau W. et al. Combination PET/CT with ¹²⁴I positron rays in metastatic follicular thyroid carcinoma. Nuklearmedizin 2002; 41: N68-71.
9 Gutzeit A, Debatin JF, Antoch G. Tumorstaging mit PET/CT: Detektion eines Zweittumors. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2004; 176: 122-4.
10 Hany TF, Steinert HC, Goerres GW. et al. PET diagnostic accuracy: improvement with in-line PET-CT system. Radiology 2002; 225: 575-81.
11 Hosten N, Kreissig R, Puls R. et al. Fusion of CT and PET data: methods and clinical relevance for planning laser-induced thermotherapy of liver metastases. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2000; 172: 630-5.
12 Lardinois D, Weder W, Hany TF. et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7.
13 Prokop M. Radiation dose and image quality in computed tomography. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2002; 174: 631-6.
14 Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, »Onko-PET III«. Eur J Nucl Med 2001; 28: 1707-23.
15 Romer W, Avril N, Dose J. et al. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 1997; 166: 62-8.
16 Schmidt S, Nestle U, Walter K. et al. Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 1⁸FDG-PET. Nuklearmedizin 2002; 41: 217-20.
17 Schoder H, Erdi YE, Larson SM. et al. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003; 30: 1419-37.
18 Violante MR, Dean PB. Improved detectability of VX2 carcinoma in the rabbit liver with contrast enhancement in computed tomography. Radiology 1980; 134: 237-9.
19 Zatz LM. Iodinated contrast media in cranial tomography. Invest Radiol 1980; 15: S155-9.
20 Zimny M, Wildberger JE, Cremerius U. et al. Combined image interpretation of computed tomography and hybrid PET in head and neck cancer. Nuklearmedizin 2002; 41: 14-21.